Clinical trials
Phase 1 Neuralgia trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
62 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 40 |
| Unknown status | 9 |
| Not yet recruiting | 4 |
| Terminated | 4 |
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biogen | 4 |
| Stanford University | 4 |
| GL Pharm Tech Corporation | 3 |
| University Children's Hospital, Zurich | 3 |
| GlaxoSmithKline | 2 |
| IlDong Pharmaceutical Co Ltd | 2 |
| Minia University | 2 |
| Relmada Therapeutics, Inc. | 2 |
| University Hospital, Clermont-Ferrand | 2 |
| iN Therapeutics Co., Ltd. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neuralgia | 62 |
| Chronic Pain | 11 |
| Pain | 10 |
| Neuralgia, Postherpetic | 5 |
| Nociceptive Pain | 4 |
| Movement Disorders | 3 |
| Osteoarthritis | 3 |
| Postoperative Pain | 3 |
| Diabetic Neuropathies | 2 |
| Headache | 2 |
Trials
Showing 26 to 50 of 62. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.